Gail H Cassell

Gail H Cassell, Ph.D.

Bio
Research
Publications

Dr. Cassell is vice president for TB Drug Development at the Infectious Disease Research Institute in Seattle, Washington, professor emeritus and former chair, Department of Microbiology, University of Alabama at Birmingham, and former vice president for scientific affairs and distinguished Lilly research scholar for infectious diseases at Eli Lilly and Company in Indianapolis, Indiana. She founded the Forum on Drug Discovery, Development and Translation, which she continues to co-chair, at the Institute of Medicine. She has a distinguished record of national service with the National Academy of Sciences, National Institutes of Health, Centers for Disease Control, and several other national and international institutions.

Affiliations:

Division of Global Health Equity, Brigham and Women's Hospital

Dr. Cassell is a leader on efforts to address multidrug-resistant tuberculosis (MDRTB). She and Barry Bloom, former dean of Harvard School of Public Health, co-lead an Institute of Medicine project on drug supply chain issues related to MDRTB. She actively advises numerous government agencies, NGOs, and foundations on the scale-up of MDRTB diagnosis and treatment in endemic areas around the world, including in Russia. Dr. Cassell is advising the GHSM Sentinel Project on pediatric drug-resistant tuberculosis, a global partnership that aims to develop and deploy evidence-based strategies to prevent child deaths from drug-resistant tuberculosis.

Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: follow-up.

Authors: Authors: Brasfield DM, Stagno S, Whitley RJ, Cloud G, Cassell G, Tiller RE.
Pediatrics 1987-01-01
View full abstract on Pubmed

Development of an aerosol model of murine respiratory mycoplasmosis in mice.

Authors: Authors: Davis JK, Thorp RB, Parker RF, White H, Dziedzic D, D'Arcy J, Cassell GH.
Infect Immun 1986-10-01
View full abstract on Pubmed

Polyclonal activation of rat splenic lymphocytes after in vivo administration of Mycoplasma pulmonis and its relation to in vitro response.

Authors: Authors: Williamson JS, Davis JK, Cassell GH.
Infect Immun 1986-05-01
View full abstract on Pubmed

Further studies on genital mycoplasmas in intra-amniotic infection: blood cultures and serologic response.

Authors: Authors: Gibbs RS, Cassell GH, Davis JK, St Clair PJ.
Am J Obstet Gynecol 1986-04-01
View full abstract on Pubmed

Ureaplasma urealyticum and its possible role in pneumonia during the neonatal period and infancy.

Authors: Authors: Rudd PT, Waites KB, Duffy LB, Stagno S, Cassell GH.
Pediatr Infect Dis 1986-01-01
View full abstract on Pubmed

Distribution of Ia antigens and T lymphocyte subpopulations in rat lungs.

Authors: Authors: Simecka JW, Davis JK, Cassell GH.
Immunology 1986-01-01
View full abstract on Pubmed

Can group- and serovar-specific proteins be detected in Ureaplasma urealyticum?

Authors: Authors: Horowitz SA, Duffy L, Garrett B, Stephens J, Davis JK, Cassell GH.
Pediatr Infect Dis 1986-01-01
View full abstract on Pubmed

Role of Ureaplasma urealyticum in amnionitis.

Authors: Authors: Cassell GH, Waites KB, Gibbs RS, Davis JK.
Pediatr Infect Dis 1986-01-01
View full abstract on Pubmed

Ureaplasmas of human: with emphasis upon maternal and neonatal infections. Future considerations: maternal and neonatal aspects.

Authors: Authors: Cassell GH.
Pediatr Infect Dis 1986-01-01
View full abstract on Pubmed

Strain differences in susceptibility to murine respiratory mycoplasmosis in C57BL/6 and C3H/HeN mice.

Authors: Authors: Davis JK, Parker RF, White H, Dziedzic D, Taylor G, Davidson MK, Cox NR, Cassell GH.
Infect Immun 1985-12-01
View full abstract on Pubmed